Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
08/05/2026 22:27
May 8 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES U.S. FDA APPROVAL EXPANDING VYVGART AND VYVGART HYTRULO FOR USE IN ALL ADULT PATIENTS LIVING WITH GMG Source text: ID:nGNXb77Rxb Further company coverage: ARGX.BR ((Reuters.Briefs@thomsonreuters.com;))
Recent news on argenx SE
See all newsBrief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles
Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP